Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Substance Use and Media Preferences

2 de noviembre de 2026 actualizado por: Ruschelle Leone, University of Colorado, Denver

The goal of this randomized clinical trial is to learn how alcohol use, cannabis use, and using both substances affect whether and how quickly people stop a video being shown to a woman. The study will recruit 312 people from the Metro-Denver area who drink alcohol and use cannabis; half of the participants will be women. The main questions it aims to answer are:

  • How do alcohol, cannabis, and their combined use affect whether participants stop the video and how quickly they do so?
  • Does alcohol use versus alcohol and cannabis use by others in the scenario affect whether and how quickly participants stop the video?

Researchers will compare four randomly assigned groups: alcohol only, cannabis only, both alcohol and cannabis, and neither substance. Participants will also be randomly assigned to one of two scenarios involving alcohol use or alcohol and cannabis use by others. These comparisons will help researchers understand how participants' own substance use and substance use by others affect their decisions to intervene.

Participants will:

  • Complete a phone call to review the study and schedule a mobile laboratory visit at their home.
  • Have their ID checked, complete a breath alcohol test to confirm no alcohol is in their system, and be weighed. Female participants will also take a pregnancy test.
  • Provide written consent and complete questionnaires so researchers can confirm eligibility before random assignment.
  • Follow their assigned substance-use condition. Participants in the cannabis-only group will smoke their usual cannabis at home while staff monitor them through Zoom. Those in the alcohol-only group will drink two weight-based alcoholic beverages, with a target blood alcohol concentration of 0.08%. Those assigned to both substances will use cannabis first and then drink alcohol. Those assigned to neither substance will not use either as part of the study.
  • Provide blood and breath samples to measure cannabis-related THC and alcohol levels.
  • Complete a task in which they can choose to stop a video being shown to a woman. Researchers will measure whether they stop the video and how long they take to do so.
  • Take part in a recorded interview about their experience and the reasons they did or did not stop the video. Researchers will analyze these interviews to better understand how substance use affects decisions.
  • Answer questions about what they believed the study was testing and their impressions of the other participants, receive an explanation of the study, and receive compensation.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Estimado)

312

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Colorado
      • Denver, Colorado, Estados Unidos, 80045
        • University of Colorado Anschutz Medical Campus
        • Contacto:
        • Investigador principal:
          • Ruschelle Leone, PhD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

21 años a 30 años (Adulto)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Provision of signed and dated informed consent form.
  2. Stated willingness to comply with all study procedures and lifestyle considerations .
  3. Aged 21-30, verified by a photo ID.
  4. Consume an alcohol quantity on a single occasion that is equal to or greater than the dose administered in the laboratory on ≥ 3 days in the past year (see Table 1).
  5. Smoked cannabis ≥ 3 days in the past year.
  6. Engaging in simultaneous alcohol and cannabis use ≥ 1 day in the past year.

Exclusion Criteria:

  1. Currently being treated or in recovery for alcohol or drug problems; currently interested in seeking treatment for drinking or drug use via self-report.
  2. Experienced an adverse event while co-using alcohol and cannabis at any time in the past 3 months.
  3. Any medical or psychiatric condition, as well as current use of a medication, that would contraindicate alcohol administration as determined by the Study Physician.
  4. Acute Psychiatric Symptomatology: elevated psychological distress as indicated by a score greater than 65 on the Brief Symptom Inventory.
  5. Self-report that a participant is trying to get pregnant, currently pregnant, or a positive pregnancy test.
  6. Combined height and weight that is either less than 6 feet tall and over 230 lbs, or over 250 lbs and over 6 ft tall as measured during the lab visit or by a valid photo ID.
  7. Current or past participation in PI Leone's research study 'Understanding the Influence of Alcohol and Media on Relationships' protocol #24-1867.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Ciencia básica
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación factorial
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Alcohol Consumption + Alcohol Consumption of Others

Participants will be assigned to drink alcohol and the others in the study will also be assigned to drink alcohol.

Participants will consume a moderate alcohol dose condition (target BrAC .08%) with the National Institute on Alcohol Abuse and Alcoholism (NIAAA) approved alcohol administration procedures.

Others in the study will be assigned to drink alcohol

Experimental: Alcohol Consumption + Alcohol/Cannabis Consumption of Others

Participants will be assigned to drink alcohol and the others in the study will be assigned to drink alcohol and consume cannabis.

Participants will consume a moderate alcohol dose condition (target BrAC .08%) with the National Institute on Alcohol Abuse and Alcoholism (NIAAA) approved alcohol administration procedures.

Others in the study will be assigned to drink alcohol and consume cannabis

Experimental: Alcohol/Cannabis Consumption + Alcohol Consumption of Others

Participants will be assigned to drink alcohol and consume cannabis; and the others in the study will be assigned to drink alcohol.

Others in the study will be assigned to drink alcohol

Participants in this group will self-administer legal-market flower cannabis Participants will consume a moderate alcohol dose condition (target BrAC .08%) with the National Institute on Alcohol Abuse and Alcoholism (NIAAA) approved alcohol administration procedures.

Experimental: Alcohol/Cannabis Consumption + Alcohol/Cannabis Consumption of Others

Participants will be assigned to drink alcohol and consume cannabis; and the others in the study will be assigned to drink alcohol and consume cannabis.

Others in the study will be assigned to drink alcohol and consume cannabis

Participants in this group will self-administer legal-market flower cannabis Participants will consume a moderate alcohol dose condition (target BrAC .08%) with the National Institute on Alcohol Abuse and Alcoholism (NIAAA) approved alcohol administration procedures.

Comparador activo: Sober + Alcohol Consumption of Others

Participants will be assigned to drink a non-alcohol control beverage; and the others in the study will be assigned to drink alcohol.

Others in the study will be assigned to drink alcohol

Participants will be assigned to a no-alcohol control beverage and to not consume cannabis.

Comparador activo: Sober + Alcohol/Cannabis Consumption of Others

Participants will be assigned to drink a non-alcohol control beverage; and the others in the study will be assigned to drink alcohol and consume cannabis.

Others in the study will be assigned to drink alcohol and consume cannabis

Participants will be assigned to a no-alcohol control beverage and to not consume cannabis.

Experimental: Cannabis Consumption + Alcohol Consumption of Others

Participants will be assigned to consume cannabis, and the others in the study will be assigned to drink alcohol.

Others in the study will be assigned to drink alcohol

Participants in this group will self-administer legal-market flower cannabis

Experimental: Cannabis Consumption + Alcohol/Cannabis Consumption of Others

Participants will be assigned to consume cannabis, and the others in the study will be assigned to drink alcohol and consume cannabis.

Others in the study will be assigned to drink alcohol and consume cannabis

Participants in this group will self-administer legal-market flower cannabis

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Intervention Likelihood
Periodo de tiempo: Up to three hours after consent

Stopping a woman from watching content during the Bystander Intervention Paradigm (Parrott et al., 2012, Leone et al., 2015). Possible scores are 0 (not stopping) to 1 (stopping).

Up to three hours after consent
Intervention Speed
Periodo de tiempo: Up to three hours after consent

The amount of time the woman watches the sexually explicit film during the Bystander Intervention Paradigm (Parrott et al., 2012, Leone et al., 2015). Scores range from 0 to 4 minutes.

Up to three hours after consent
Number of Bystander Barriers
Periodo de tiempo: Up to four hours after consent

Count number of barriers experienced during the paradigm via a semi-structured interview.

Up to four hours after consent
Number of Bystander Facilitators
Periodo de tiempo: Up to four hours after consent

Count number of facilitators experienced during the paradigm via a semi-structured interview.

Up to four hours after consent

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de mayo de 2027

Finalización primaria (Estimado)

1 de marzo de 2031

Finalización del estudio (Estimado)

1 de marzo de 2031

Fechas de registro del estudio

Enviado por primera vez

2 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

2 de noviembre de 2026

Publicado por primera vez (Actual)

6 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

6 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 26-1956
  • R01AA032801 (Subvención/contrato del NIH de EE. UU.)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

IPD will be available in the NIAAA Data Archive.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir